The UK and US have announced a major bilateral deal that will keep no import taxes on UK medicine exports being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost spending on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these vital exports will remain at nothing for a timeframe of three years.
This development follows earlier warnings to hike tariffs on patented pharmaceutical imports, with increases mentioned reaching double the cost.
"This agreement with the UK bolsters the international landscape for cutting-edge drugs and brings much-needed balance to transatlantic drug exports," an announcement noted.
Trade Impact
Medicines represent one of the the United Kingdom's largest goods shipped to the US, which is clearly the primary market for major British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to September, the UK sold medicines totaling over eleven billion pounds to the US. This figure represented 17.4% of total UK exports in that period.
"This guarantee protects work, increases capital expenditure and paves the way for the UK to emerge as a global hub for medical research," a government official remarked.
Specific British Pledges
The pact involves several key pledges from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, repayments topped 20%.
Recent Tensions
The deal takes place against a long-running row between the pharmaceutical industry and the ministers over spending levels and approval rates.
This friction were intensified by arguments that US patients were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
One official stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the last ten years.
